Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ0P6A
|
|||
| Drug Name |
PBF-999
|
|||
| Synonyms |
CHEMBL3942498; SCHEMBL15905362; BDBM247392; SB18883; US9447095, 42; 5-bromo-4-N-prop-2-ynyl-2-(1,2,4-triazol-1-yl)pyrimidine-4,6-diamine; 1620909-95-6
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [2] | ||
| Company |
Palobiofarma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H8BrN7
|
|||
| Canonical SMILES |
C#CCNC1=NC(=NC(=C1Br)N)N2C=NC=N2
|
|||
| InChI |
1S/C9H8BrN7/c1-2-3-13-8-6(10)7(11)15-9(16-8)17-5-12-4-14-17/h1,4-5H,3H2,(H3,11,13,15,16)
|
|||
| InChIKey |
OQCWNHHZPYJHQR-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Antagonist | [3] |
| Phosphodiesterase 10A (PDE10) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Parkinson's disease | ||||
| Alcoholism | ||||
| Purine metabolism | ||||
| Morphine addiction | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| Purine Metabolism | ||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | NGF-independant TRKA activation | |||
| Adenosine P1 receptors | ||||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| cGMP effects | ||||
| WikiPathways | Nucleotide GPCRs | |||
| Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02208934) Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03786484) Study of PBF-999 in Solid Tumour Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Palobiofarma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.